{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 40,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/32",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "list",
      "text": "Generally well tolerated\nFour partial responses as a monotherapy agent in the post PD-1/PD-L1 patient population\nSmall cell lung cancer, mesothelioma, and melanoma (two patients)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a52f218c-ee1c-4216-9ac5-f84a6d4c4377",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.53,
        "y": 0.45
      },
      "kind": "list",
      "text": "Abbreviated CTX-471 dose escalation into the PD-1 regimen, followed by a cohort expansion\nPost PD-1/PD-L1 Salvage Study\nClinical collaboration with Merck",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e845df5e-a366-4eec-80cb-f0b722d1b792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.28,
        "x": 0.12,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Phase 1b study fully enrolled",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79b3c052-61c7-4499-b43d-edc7923a0f9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.53,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Initiating Phase 1b of CTX-471 with Keytruda®",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dae29c2-a513-4746-8dd4-661096af9e9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.09,
        "y": 0.14
      },
      "kind": "title",
      "text": "CTX-471 Clinical Development Plans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dca8fa6f-3af7-40ee-9ec8-413e87fa81e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}